Business
Lakewood-Amedex Biotherapeutics Announces Direct Listing on Nasdaq; Shares Trading Under the Symbol "LABT"
Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced that shares of the Company's common stock began trading today on the Nasdaq Capital Market ("Nasdaq") under the ticker symbol "LABT".
About this update from Lakewood-amedex Biotherapeutics Inc.
[{"type":"text","content":"SARASOTA, Fla., April 23, 2026 /PRNewswire/ — Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced that shares of the Company's common stock began trading today on the Nasdaq Capital Market ("Nasdaq") under the ticker symbol "LABT".","length":447,"tagName":"p"},{"type":"image","alt":"Lakewood-Amedex Biotherapeutics","displaySize":"","headline":null,"caption":"Lakewood-Amedex Biotherapeutics","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":265,"url":"https://media.zenfs.com/en/prnewswire.com/ec3c0ac839ffd32dbb2538ff07a4e38a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/LC3w2lVi065kRnLfNPE_uw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTQ2Nw--/https://media.zenfs.com/en/prnewswire.com/ec3c0ac839ffd32dbb2538ff07a4e38a","width":400,"height":265}},"href":"https://mma.prnewswire.com/media/2963822/Lakewood_Amedexs_FINAL_Logo.html","hrefExternal":true},{"type":"text","content":""We are pleased to announce that Lakewood-Amedex Biotherapeutics' common stock began trading on the Nasdaq Stock Market today," said Doug Manion, M.D., Chairman of the Board. "This listing is a notable achievement marking a new chapter for our company enabling the accelerated development of our Bisphosphocin® class of compounds, including our lead product, Nu-3, as a potential treatment for infected diabetic foot ulcers (iDFU)."","length":456,"tagName":"p"},{"type":"text","content":""We plan to initiate a Phase 2a clinical trial in iDFU shortly," stated Kelvin Cooper, Ph.D., Chief Executive Officer and Senior Vice President of Research and Development. "Close to 40 million people in the US live with diabetes, and around one-third will develop a DFU in their life, of which about 50% will be infected at some point. Additionally, numerous patients experience more than one of these events in their life, and antibiotic-resistant bacterial strains are a major concern for the treatment of these patients. We look forward to accelerating our work targeting this major unmet need."","length":619,"tagName":"p"},{"type":"text","content":"About Lakewood-Amedex Biotherapeutic...